FFB News and Press Releases

  • When it was his turn to take the stage at a press conference at The Children’s Hospital of Philadelphia (CHOP), Corey Haas got up from his seat in the auditorium and walked effortlessly up the four steps in front of him. Without hesitation, he crossed the stage, stepped around the table and took his seat next to Dr. Jean Bennett. His white cane was nowhere to be seen.
  • Neurotech’s innovative treatment employing Encapsulated Cell Technology (ECT) demonstrated a biological effect after 12 months for people with retinitis pigmentosa (RP), Usher syndrome, and choroideremia participating in two Phase II/III clinical trials. Both trials are being funded in-part by the Foundation Fighting Blindness.
  • Dr. John Flannery, a Foundation-funded researcher, recently restored some visual ability in mice with retinitis pigmentosa by injecting a gene therapy that helps make up for the loss of photoreceptors.
  • The path to developing gene therapy treatments for retinal degenerations, and other diseases, has been an arduous one. Foundation Fighting Blindness researchers took on much of the early pioneering work in this field and, thanks to their foresight and dedication, gene therapy is emerging as one the greatest breakthroughs in medical research history. These milestones mark the progression of gene therapy for retinal degenerative diseases over two decades.

Pages